Dallas、TXにおける非小細胞肺癌の臨床試験
Dallasとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する52件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
被験者募集中第3相
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
被験者募集中第1/2相
- UT Southwest Simmons Cancer Center, Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
被験者募集中第1相
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
被験者募集中第1相
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- Texas Oncology Dallas, Dallas
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- 他2件
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- 他2件
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
被験者募集中第1相
- Research Site, Dallas
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
被験者募集中第1/2相
- Baylor, Scott and White Research Institute, Dallas
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
被験者募集中第1相
- UT Southwestern Medical Center at Dallas, Dallas
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- Texas Oncology Sammons Cancer Center, Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Site, Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
被験者募集中第1相
- NEXT - Dallas, Dallas
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
被験者募集中観察研究
- UT Southwestern Medical Center, Dallas
A Study of KK2269 in Adult Participants With Solid Tumors
被験者募集中第1相
- The University of Texas Southwestern Medical Center, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第3相
- The University of Texas Southwestern Medical Center at Dallas, Dallas
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
被験者募集中第1相
- Ut Southwestern, Dallas
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
被験者募集中第3相
- Texas Oncology, Dallas
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
被験者募集中第2相
- Baylor Charles A. Sammons Cancer Center, Dallas
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
被験者募集中第1/2相
- Texas Oncology - DFW, Dallas
A Study of DM005 in Patients With Advanced Solid Tumors
被験者募集中第1/2相
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
被験者募集中第1相
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- 他2件
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
被験者募集中第2相
- Texas Oncology - DFW, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
被験者募集中早期第1相
- University of Texas Southwestern Medical Center, Dallas
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
Study of XB010 in Subjects With Solid Tumors
被験者募集中第1相
- Baylor University Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
被験者募集中第1相
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
被験者募集中第1相
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
被験者募集中第1相
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
被験者募集中第1相
- Sarah Cannon Research Institute at Mary Crowley, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
被験者募集中第1/2相
- UT Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Mary Crowley Cancer Research, Dallas
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
被験者募集中第2相
- UT Southwestern Medical Center, Dallas
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
被験者募集中第2相
- University of Texas Southwestern Medical Center, Dallas
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
被験者募集中第3相
- University of Texas Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
被験者募集中第1相
- Mary Crowley Cancer Research, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- NEXT Dallas, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
被験者募集中第1/2相
- Research Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
被験者募集中第1/2相
- NEXT Oncology Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
被験者募集中第1相
- Dren Investigational Site, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Dallas
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
被験者募集中観察研究健康なボランティア歓迎
- Baylor Scott and White Research Institute, Dallas
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY120件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH56件の研究
- Washington, DC55件の研究
Dallasにおける他の研究
- 乳がん55件の研究
- 転移性癌42件の研究
- 心不全42件の研究
- がん（全種類）37件の研究
- 前立腺がん36件の研究
- 大腸癌33件の研究
- 肥満症30件の研究
- 卵巣がん28件の研究
- 膀胱癌27件の研究
- 肺がん27件の研究
- 子宮内膜がん24件の研究
- 心血管疾患23件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。